Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction

mRCC: Real-world experience: achieving efficacy beyond clinical trials

mRCC: Are we doing all we can to manage adverse events?

mRCC: Understanding the patient's perspective

mRCC: Panel discussion

mRCC: Closing remarks

Optimizing survival in advanced prostate cancer: Welcome and introduction

Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival

Optimizing survival in advanced prostate cancer: CHAARTED: What are the implications for the future?

Optimizing survival in advanced prostate cancer: Learnings from real life practice

Optimizing Survival in Advanced Prostate Cancer: Conclusion

Overall survival update from the BREAK-3 study

Early events found to trigger lung cancer twenty years before diagnosis

Cancer Core Europe: Introduction

Cancer Core Europe: National Center for Tumor Diseases

Cancer Core Europe: Vall d'Hebron Institute of Oncology

Cancer Core Europe: Cancer Research UK Cambridge Institute

Cancer Core Europe: Karolinska Institute

Cancer Core Europe: Institut Gustave Roussy

Cancer Core Europe: Netherlands Cancer Institute

Cancer Core Europe: Questions and answers

Cancer Core Europe: Consortium to address the care-research continuum challenge

ESMO 2014: News Roundup

ESMO 2014 Editor's roundup

Ipilimumab extends relapse-free survival in resectable melanoma

Prognostic biomarkers will detect lung cancer at earlier stages

vandetanib improves PFS in thyroid cancer

E-hospital: Fully coordinated cancer care and research in Europe

ESMO Highlights: Breast cancer

Combination of capecitabine and bevacizumab improves progression-free survival in metastatic breast cancer

Research shows chemotherapy has no negative effects on babies in utero

Importance of gynaecological surgeons and multidisciplinary strategies in advanced ovarian cancer

Raising awareness about head and neck cancer through the Make Sense campaign

Cancer care in developing countries

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

Young oncologists bridging the gap between translational and clinical cancer research

Questions raised about the future of lung cancer vaccination?

Cancer care as a human right in low-income countries

PD-L1 protein a possible immunotherapy target in mesothelioma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

EORTC and the management of clinical trial data

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Financial impact of a cancer diagnosis

Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma

Molecular targeting in cancer and the impact on personalised medicine

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Phase III trial results raise questions about the future of lung cancer vaccination

Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Adding cediranib to chemo improves PFS for metastatic cervical cancer

Helping cancer patients make sense of risk

Reducing nausea and vomiting associated with cisplatin-based chemotherapy with rolapitant

Rare cancers and the difficulties in making clinical decisions

Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Study shows chemotherapy and radiotherapy are safe for babies in utero

Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Second-line afatinib significantly improves PFS in metastatic head and neck cancer